GemPharmatech
GemPharmatech (江苏集萃药康) is a publicly listed (SSE:688046) Chinese preclinical research company that develops 22,000+ genetically engineered mouse models and offers integrated pharmacology, efficacy, and antibody discovery services to global academic institutions, CROs, and pharmaceutical companies.
- Company typePrivate
- Founded2017
- HeadquartersNanjing, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What GemPharmatech does
GemPharmatech (江苏集萃药康生物科技股份有限公司), founded in 2017 and headquartered in Nanjing, China, is a publicly listed (SSE:688046) preclinical research company specializing in genetically modified mouse models and integrated drug discovery services. The company leverages CRISPR/Cas9 and ES-targeting gene editing to build and commercialize an internal catalog of more than 22,000 self-developed model strains, organized into flagship product lines: the NCG severely immunodeficient series, the Spot Mouse (KOAP) genome-wide cKO/KO library, humanized models across gene, cell/tissue, immune-reconstitution, and microbiome modalities, disease models spanning oncology, metabolic, autoimmune, neurological, hematological, and rare disease indications, Cre/Dre tool mice, and wild-derived chromosome substitution lines. The proprietary NeoMab™ fully human antibody transgenic mouse platform extends the company into therapeutic antibody discovery, an area highlighted by its October 2025 research collaboration with Memorial Sloan Kettering Cancer Center.
The company monetizes through four revenue streams: (1) one-time licensing-style sales of catalog mouse models via a direct sales hotline, regional sales managers, and an online e-commerce shop; (2) professional services for model customization (transgenic, KO, KI, point mutations), custom breeding, and microbial/SNP quality testing; (3) preclinical pharmacology and efficacy services covering target validation, pharmacodynamics, and non-GLP safety assessment; and (4) antibody discovery via NeoMab™. Customers span 1,100+ academic and government research institutions and 1,000+ pharmaceutical/biotech and CRO customers across China, the US, and other global markets. Operations are supported by a 45,000+ m² SPF-grade facility footprint with 300,000 cage positions, AAALAC International and ISO 9001 certifications, designation as a National High-Tech Enterprise, and a 10-entity corporate structure including an overseas US subsidiary.
GemPharmatech reports a multi-year revenue ramp consistent with ~16% annual growth, reaching approximately $113.5M in 2025 with EBITDA of approximately $36.8M. Cumulative scientific output of 6,315+ SCI publications (64,822 total impact factor) and 300+ completed IND-supporting projects demonstrate the company's embedded role in translational research. The business model emphasizes scale, catalog depth, and one-stop vertical integration from gene editing through in vivo efficacy evaluation, positioning GemPharmatech as a China-based platform competitor to global preclinical model suppliers.
GemPharmatech firmographics
Firmographics- Name
- GemPharmatech
- Legal name
- 江苏集萃药康生物科技股份有限公司 (GemPharmatech Co., Ltd.)
- Website
- https://gempharmatech.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- GemPharmatech (江苏集萃药康) is a publicly listed (SSE:688046) Chinese preclinical research company that develops 22,000+ genetically engineered mouse models and offers integrated pharmacology, efficacy, and antibody discovery services to global academic institutions, CROs, and pharmaceutical companies.
- Ownership category
- akta.pro rank
GemPharmatech industry classification
Industry- Product category
- Preclinical Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where GemPharmatech is headquartered
LocationHeadquarters
- HQ city
- Nanjing
- HQ country
- China
- HQ region
- Asia
Offices8 records
Markets served
GemPharmatech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Mouse Model Sales: Sale of genetically modified mouse models including KO/CKO models, humanized models, disease models, NCG immunodeficient mice, wild mouse lines, and tool mice (Cre/Dre)
- Technical Services: Model customization (transgenic, KO, KI, point mutations), custom breeding, quality testing (microbial and SNP detection), animal facility management services
- Pharmacology and Efficacy Services: Preclinical pharmacology and efficacy evaluation services including target validation, pharmacodynamic studies, and non-GLP safety assessment for oncology, metabolic, autoimmune, and neurological diseases
- Antibody Discovery Services: Full human antibody discovery services using NeoMab™ platform for therapeutic antibody development
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Mouse model pricing varies by strain, genotype, and quantity |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
GemPharmatech product offering
Product offeringCore offering
GemPharmatech develops, breeds, and supplies genetically engineered mouse models (KO/CKO, humanized, immunodeficient NCG, disease, wild-derived, and Cre/Dre tool strains) using CRISPR/Cas9 and ES targeting technologies. The company provides one-stop preclinical research services including custom model generation, breeding, quality testing, pharmacology/efficacy evaluation, and antibody discovery via its NeoMab™ platform to global research institutions, CROs, and pharmaceutical companies.
Product overview
GemPharmatech is a comprehensive mouse model research and development company offering a unified platform of genetically engineered mouse models and preclinical research services. The core portfolio includes the NCG immunodeficient mouse model, Humanized Models, Spot Mouse (KOAP) knockout library, Disease Models, Wild Mouse chromosome substitution lines, and Cre/Dre Tool Mice. Supporting services include the NeoMab™ antibody discovery platform, PDX and CDX model resources, plus model customization, custom breeding, quality control testing, and pharmacology/efficacy services. The company leverages CRISPR/Cas9 and ES targeting technologies to serve global research institutions, CRO companies, and pharmaceutical enterprises.
Differentiator
Problem solved
Functional benefit
Brands
- NeoMab™: A fully human antibody transgenic mouse platform used for therapeutic antibody discovery, as referenced in the collaboration with Memorial Sloan Kettering Cancer Center.
Products and services
- NCG Mouse Model A severely immunodeficient mouse model developed by GemPharmatech through CRISPR/Cas9 gene editing to knock out the Prkdc and Il2rg genes in NOD/ShiltJGpt mice. Features T cell, B cell, and NK cell deficiency, making it the most comprehensive immunodeficient mouse model available. Intended for oncology, immunology, and human cell/tissue engraftment research by pharmaceutical, biotech, and academic customers.
- Humanized Mouse Models Portfolio of humanized mouse models including gene humanization (e.g., PD1, CD3E, CTLA4, OX40 humanized strains), cell and tissue humanization, immune reconstitution strains, and flora humanization models. Provides tools for targeted human therapy drug development and immuno-oncology research for pharmaceutical and biotech R&D teams.
- Spot Mouse (Knockout All Project / KOAP) Large-scale cKO/KO mouse model library covering all protein-coding genes in the mouse genome, with over 12,000 knockout strains and 10,000+ conditional knockout strains already completed and 300+ ready-to-ship lines deliverable within 7 days. Commercialized gene knockout model product line intended for academic and pharmaceutical research use.
- Disease Mouse Models Validated disease mouse models with confirmed phenotypes covering oncology, metabolic, cardiovascular, autoimmune, neurological, hematological, and rare disease research areas. Over 1,000 rigorously phenotyped models and 20,000+ disease research-related models available for preclinical drug efficacy and mechanism studies.
- Wild Mouse (Wild-derived Chromosome Substitution Lines) Wild-derived mouse strains with enhanced genetic diversity developed by backcrossing wild mice to the C57BL/6JGpt inbred strain and creating chromosome substitution lines. Includes Chromosome 1 and Chromosome 17 substitution lines applied primarily in metabolic, neurological, and immunological research.
- Cre/Dre Tool Mice Cre, Flpo, and Dre recombinase-mediated tool mice enabling site-specific DNA cutting and recombination in vivo and in vitro. Includes over 200 Cre strains and 50+ reporter mouse strains covering neuroscience, immunology, and other research applications.
- NeoMab™ Fully Human Antibody Transgenic Mouse Platform Proprietary fully human antibody transgenic mouse platform for therapeutic antibody discovery, enabling generation of fully human antibodies with reduced immunogenicity risks. Used in antibody discovery services and supported by a research collaboration with Memorial Sloan Kettering Cancer Center.
- PDX Resources (Patient-Derived Xenograft Models) Patient-derived xenograft (PDX) model resources and services for preclinical oncology drug efficacy testing using patient-derived tumor tissues implanted into immunodeficient mice.
- CDX Cell Line-Derived Xenograft Models Cell line-derived xenograft (CDX) model resources using established cancer cell lines for preclinical cancer drug evaluation.
- Model Customization Services Custom gene editing model development services for clients requiring specific transgenic (TG), knockout (KO), knock-in (KI), or point mutation (PM) mouse models, built using CRISPR/Cas9 and ES targeting technologies.
- Pharmacology and Efficacy Evaluation Services Preclinical pharmacology and efficacy evaluation services including target validation, pharmacodynamic studies, in vivo efficacy studies, and non-GLP safety assessment covering oncology, metabolic, autoimmune, and neurological disease areas. Supports IND filing programs for pharmaceutical and biotech clients.
- Custom Breeding Services Custom breeding services including biological purification, assisted reproduction, sperm/embryo cryopreservation and recovery, and contract breeding for client-owned mouse strains.
- Quality Control Testing Services Microbiological testing and SNP genotyping services for mouse colonies, plus animal facility management (动物房托管) services with standardized operations, strict environmental and microbiological monitoring, and a comprehensive service system.
Quantifiable outcome
- Delivery within 7 days for 300+ ready-to-ship gene-edited mouse models
- +1 more outcomes
Companies that use GemPharmatech
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
GemPharmatech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
GemPharmatech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Memorial Sloan Kettering Cancer Center (MSK Cancer Center)coreResearch collaboration to accelerate therapeutic antibody discovery using GemPharmatech's NeoMab® platform. The non-exclusive agreement grants MSK researchers access to GemPharmatech's preclinical resources, aiming to develop fully human therapeutic antibodies with reduced development timelines and immunogenicity risks for new cancer therapies.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
GemPharmatech competitors and assessment
Company assessmentDirect peers
- Cyagen Biosciences: China-headquartered provider of genetically engineered mouse/rat models, custom breeding, and preclinical services. Direct competitor to GemPharmatech across KO/CKO catalogs, humanized models, and preclinical efficacy offerings.
- Biocytogen Pharmaceuticals: Beijing-based biotech combining proprietary humanized antibody mouse platforms (RenMab, RenLite) with gene editing and preclinical services. Closest direct rival to GemPharmatech's NeoMab antibody discovery platform and model catalog.
- Shanghai Model Organisms Center (SMOC): Chinese developer of knockout, knockin, and humanized mouse models with related preclinical services. Overlaps directly with GemPharmatech's Spot Mouse program and disease/humanized model portfolio for domestic and academic customers.
- The Jackson Laboratory: US-based nonprofit supplying the largest catalog of genetically defined mice plus preclinical research services. The global benchmark for mouse model distribution and a direct competitor in humanized and immunodeficient models.
- Taconic Biosciences: Global supplier of genetically engineered rodent models and preclinical services, with strength in humanized and immuno-oncology models. Comparable model catalog and service breadth serving pharma, biotech, and academic customers.
- Inotiv: US-headquartered contract research organization offering research models and preclinical services following the Envigo merger. Overlaps with GemPharmatech's model supply and preclinical efficacy operations for global pharma clients.
Broad incumbents
- Charles River Laboratories: Global leader in preclinical CRO services including research animal models, safety assessment, and biologics manufacturing. A broad incumbent whose Research Models & Services segment competes directly with GemPharmatech across the model and preclinical value chain.
- Crown Bioscience: Global preclinical CRO specializing in oncology and immuno-oncology drug development using proprietary PDX and humanized mouse platforms. Competes in the preclinical pharmacology and PDX/CDX service categories where GemPharmatech also operates.
- WuXi AppTec: China's largest CRO/CDMO operating across discovery, preclinical, and clinical services. Although not focused purely on mouse models, its preclinical and biologics testing arms overlap with GemPharmatech's service portfolio for both Chinese and global customers.
Regional players
- Ozgene: Australia-based provider of genetically engineered mouse models and related services. Comparable in technology and product offering but primarily serves the Asia-Pacific research market rather than competing directly in China.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
GemPharmatech social profiles
Digital presenceGemPharmatech compliance and trust
Trust signalCompliance2 records
GemPharmatech financial estimates
Financial estimateRevenue estimate
Valuation estimate
GemPharmatech leadership team
Management profileNumber of profiles
Profiles1 record
GemPharmatech subsidiaries and ownership
Company hierarchySubsidiaries7 records
GemPharmatech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GemPharmatech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GemPharmatech
What does GemPharmatech do?
GemPharmatech develops, breeds, and supplies genetically engineered mouse models (KO/CKO, humanized, immunodeficient NCG, disease, wild-derived, and Cre/Dre tool strains) using CRISPR/Cas9 and ES targeting technologies. The company provides one-stop preclinical research services including custom model generation, breeding, quality testing, pharmacology/efficacy evaluation, and antibody discovery via its NeoMab™ platform to global research institutions, CROs, and pharmaceutical companies.
Is GemPharmatech a public or private company?
GemPharmatech is a private company. It is classified as public and is currently operating.
When was GemPharmatech founded?
GemPharmatech was founded in 2017. It employs 1,001 to 5,000 people.
Where is GemPharmatech based?
GemPharmatech is headquartered in Nanjing, China, in the Asia region.
How does GemPharmatech make money?
Four revenue lines are on record. Mouse Model Sales are the primary driver. The others are technical Services, pharmacology and Efficacy Services and antibody Discovery Services.
Who are GemPharmatech's main competitors?
Direct peers on record are Cyagen Biosciences, Biocytogen Pharmaceuticals, Shanghai Model Organisms Center (SMOC), The Jackson Laboratory, Taconic Biosciences and Inotiv. Broad incumbents are Charles River Laboratories, Crown Bioscience and WuXi AppTec. Ozgene is listed as a regional player.
Does GemPharmatech have an API?
No public API is recorded for GemPharmatech.
What industry is GemPharmatech in?
GemPharmatech's product category is Preclinical Research Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 5417 and its SIC code is 8731.